Healing

BPC-157

Also known as: Body Protection Compound-157, Pentadecapeptide BPC 157

Preclinical
Share:

Buy in shop

BPC-157 from $59/kit

5 verified vendors, ≥99% purity, COAs included.

Compare prices

Key Facts: BPC-157

Category
Healing
FDA Status
Not FDA Approved
Clinical Status
Preclinical - FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026; formal FDA publication pending)
Administration
Subcutaneous injection near injury site, or systemic
Typical Dose
250-500 mcg twice daily
Frequency
1-2x daily
Duration
4-12 weeks in most research protocols
Also Known As
Body Protection Compound-157, Pentadecapeptide BPC 157

Mechanism of Action

The leading hypothesis is that BPC-157 promotes new blood vessel growth by upregulating the VEGFR2 receptor, the same receptor that drives angiogenesis, and by tapping into the nitric oxide system through the Akt-eNOS pathway. Better blood supply to injured tissue would, in theory, speed healing of tendons, muscle, and gut lining. Animal work also points to anti-inflammatory effects and interaction with growth-factor signaling. It is worth being blunt here: these mechanisms are mostly worked out in rodents, and the exact molecular target of BPC-157 has never been definitively pinned down. Treat the pathway story as a well-supported hypothesis, not settled fact.

Research Summary

The preclinical record is genuinely large. A 2025 narrative review in the journal Biomedicines counted hundreds of published animal studies showing BPC-157 accelerating healing across tendon, muscle, bone, gut, liver, and nervous-system injury models. The problem is the human side is nearly empty. That same review found only three published human pilot studies (knee pain injections, bladder injections for interstitial cystitis, and an intravenous safety trial) and concluded BPC-157 should be treated as investigational and not recommended for clinical use until proper trials exist. Pharmacokinetic work in rats and dogs found a very short elimination half-life (under 30 minutes after injection) and rapid breakdown into amino acid fragments, which raises real questions about how oral capsules sold online could deliver an intact peptide. Bottom line: lots of promising animal data, no completed randomized controlled trials in people, and no regulatory approval anywhere.

Trial Progress:Preclinical
Pre
I
II
III
IV
FDA

Dosing Information

Animal Studies·Primarily animal/preclinical research

Note: Animal study doses may not translate directly to humans.

Typical Dosing

Community experience

Common Dose

250-500 mcg twice daily

Range

200-1,000 mcg per day total

Frequency

1-2x daily

Often injected subcutaneously near injury site for localized healing. Systemic administration also common. Many users split into morning and evening doses.

Research Dosing

Scientific studies

Doses observed in research studies

Duration

4-12 weeks in most research protocols

Administration

Subcutaneous injection near injury site, or systemic

Timing & Administration

Best Time to Take

Morning and evening (or near injury site timing)

1-2 times daily, consistent timing

Food Recommendation

With or without food

Why This Timing?

BPC-157 has systemic healing effects. Split dosing maintains stable levels. Can be timed around activity for injury healing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Generally well-tolerated in preclinical studies
  • Nausea
  • Dizziness
  • Injection site reactions
  • Fatigue
  • Headache
  • May trigger histamine release - use caution with MCAS or histamine sensitivity
  • Potential concern for tumor promotion (angiogenesis)
  • Limited long-term human safety data

References

Research This Peptide Further

Buy in shop

BPC-157 from $59/kit

5 verified vendors, ≥99% purity, COAs included.

Compare prices

Frequently Asked Questions

What does BPC-157 do?

BPC-157 is a synthetic 15-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) based on a fragment of a protective protein found in human gastric juice. It is studied almost entirely in animals for tendon, ligament, gut, and tissue healing, and it has racked up hundreds of preclinical papers. The catch: it is not approved by any regulator for any use, and the human evidence is a handful of small pilot studies, not real clinical proof.

How does BPC-157 work?

The leading hypothesis is that BPC-157 promotes new blood vessel growth by upregulating the VEGFR2 receptor, the same receptor that drives angiogenesis, and by tapping into the nitric oxide system through the Akt-eNOS pathway. Better blood supply to injured tissue would, in theory, speed healing of tendons, muscle, and gut lining. Animal work also points to anti-inflammatory effects and interaction with growth-factor signaling. It is worth being blunt here: these mechanisms are mostly worked out in rodents, and the exact molecular target of BPC-157 has never been definitively pinned down. Treat the pathway story as a well-supported hypothesis, not settled fact.

Is BPC-157 FDA approved?

No, BPC-157 is not currently FDA approved. Current status: Preclinical - FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026; formal FDA publication pending)

What are the side effects of BPC-157?

Reported side effects include: Generally well-tolerated in preclinical studies, Nausea, Dizziness, Injection site reactions, Fatigue. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of BPC-157?

Community-reported common dose: 250-500 mcg twice daily (1-2x daily). Range: 200-1,000 mcg per day total. Administration: Subcutaneous injection near injury site, or systemic. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with BPC-157 or used in similar applications.

TB-500

Preclinical

TB-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. Most TB-500 products reproduce the short LKKTETQ sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. Here is the honest part: there are essentially no completed human trials of the TB-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing.

Healing

GHK-Cu

Clinical Trials

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.

Skin & Hair

Pentadecapeptide

Preclinical

Pentadecapeptide almost always means BPC-157, a synthetic 15-amino-acid chain (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein found in human gastric juice. It is one of the most hyped 'healing' peptides online, marketed for tendon, gut, and muscle repair, but here is the catch: essentially all of the supporting evidence is from rats and mice. There is no FDA approval and no completed human clinical trial proving it does any of this.

Healing

Thymosin Beta-4

Clinical Trials

Thymosin beta-4 (Tbeta4) is a small 43 amino acid peptide found in nearly every cell in the body, originally isolated from the thymus. Its main job is binding and sequestering G-actin, the building block of the cell's internal scaffolding, which lets it influence cell movement, wound repair, and tissue regeneration. It is researched heavily for healing of skin, cornea, and heart tissue, but it is not an FDA-approved drug. (The injectable sold as TB-500 is a synthetic fragment marketed as related to Tbeta4, not the full natural peptide.)

Healing

Ziconotide

FDA

Ziconotide is a real, FDA-approved painkiller pulled from the venom of a marine cone snail. It is not an opioid, and unlike morphine, people do not build tolerance to it over time. The catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning.

Healing

Wolverine Stack

Preclinical

The Wolverine Stack is not a single drug. It is a popular nickname for combining two regenerative peptides, BPC-157 and TB-500 (a synthetic fragment of thymosin beta-4), usually injected together for injury recovery, tendon and soft-tissue repair, and inflammation. Neither peptide is FDA-approved for human use, and the combination itself has never been tested in a human clinical trial. Almost all supporting data is from animal studies on the individual peptides.

Peptide Blend

Want updates on BPC-157 research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.